MX2017004311A - Anticuerpos del receptor del factor de necrosis tumoral inducido por glucocorticoide (gitr) y metodos de uso de los mismos. - Google Patents
Anticuerpos del receptor del factor de necrosis tumoral inducido por glucocorticoide (gitr) y metodos de uso de los mismos.Info
- Publication number
- MX2017004311A MX2017004311A MX2017004311A MX2017004311A MX2017004311A MX 2017004311 A MX2017004311 A MX 2017004311A MX 2017004311 A MX2017004311 A MX 2017004311A MX 2017004311 A MX2017004311 A MX 2017004311A MX 2017004311 A MX2017004311 A MX 2017004311A
- Authority
- MX
- Mexico
- Prior art keywords
- gitr
- glucocorticoid
- necrosis factor
- tumor necrosis
- factor receptor
- Prior art date
Links
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 title abstract 2
- 239000003862 glucocorticoid Substances 0.000 title abstract 2
- 102000003298 tumor necrosis factor receptor Human genes 0.000 title abstract 2
- 101100425749 Mus musculus Tnfrsf18 gene Proteins 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2086—IL-13 to IL-16
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462059458P | 2014-10-03 | 2014-10-03 | |
| PCT/US2015/054010 WO2016054638A1 (en) | 2014-10-03 | 2015-10-05 | Glucocorticoid-induced tumor necrosis factor receptor (gitr) antibodies and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017004311A true MX2017004311A (es) | 2017-12-07 |
Family
ID=54325751
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017004311A MX2017004311A (es) | 2014-10-03 | 2015-10-05 | Anticuerpos del receptor del factor de necrosis tumoral inducido por glucocorticoide (gitr) y metodos de uso de los mismos. |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US10463732B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3201232A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2017531427A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20170062485A (cg-RX-API-DMAC7.html) |
| CN (1) | CN107250159A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2015327781A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112017006825A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2962976A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL251389A0 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2017004311A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2017115315A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2016054638A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (117)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104994873B (zh) * | 2012-10-04 | 2017-12-22 | 达纳－法伯癌症研究所公司 | 人单克隆抗‑pd‑l1抗体和使用方法 |
| CA2933707A1 (en) | 2013-12-20 | 2015-06-25 | Fred Hutchinson Cancer Research Center | Tagged chimeric effector molecules and receptors thereof |
| CA2949998A1 (en) | 2014-05-28 | 2015-12-03 | Agenus Inc. | Anti-gitr antibodies and methods of use thereof |
| PT3151921T (pt) | 2014-06-06 | 2019-11-21 | Bristol Myers Squibb Co | Anticorpos contra recetor do fator de necrose tumoral induzido por glicocorticoide e utilizações dos mesmos |
| IL252295B2 (en) | 2014-12-19 | 2023-10-01 | Dana Farber Cancer Inst Inc | Chimeric antigen receptors and methods of using them |
| EP3288570A4 (en) | 2015-04-29 | 2018-11-21 | Fred Hutchinson Cancer Research Center | Modified stem cells and uses thereof |
| ES2810856T3 (es) | 2015-06-03 | 2021-03-09 | Bristol Myers Squibb Co | Anticuerpos ANTI-GITR para diagnóstico de cáncer |
| AU2016297249B2 (en) | 2015-07-23 | 2020-11-12 | Inhibrx Biosciences, Inc. | Multivalent and multispecific GITR-binding fusion proteins |
| BR112018010172A2 (pt) | 2015-11-19 | 2018-11-21 | Bristol Myers Squibb Co | anticorpos contra receptor de fator de necrose de tumor induzido por glicocorticoide (gitr) e usos dos mesmos |
| CN108883173B (zh) | 2015-12-02 | 2022-09-06 | 阿吉纳斯公司 | 抗体和其使用方法 |
| EP3452082A1 (en) | 2016-05-04 | 2019-03-13 | Fred Hutchinson Cancer Research Center | Cell-based neoantigen vaccines and uses thereof |
| AU2017278193B9 (en) | 2016-06-10 | 2024-02-01 | Regeneron Pharmaceuticals, Inc. | Anti-GITR antibodies and uses thereof |
| CN116903741A (zh) | 2016-06-20 | 2023-10-20 | 科马布有限公司 | 特异性结合于pd-l1的抗体或其抗原结合片段及其用途 |
| EP4512829A3 (en) | 2016-07-14 | 2025-06-11 | Bristol-Myers Squibb Company | Antibodies against tim3 and uses thereof |
| KR102534568B1 (ko) * | 2016-07-22 | 2023-05-18 | 다나-파버 캔서 인스티튜트 인크. | 글루코코르티코이드-유도된 종양 괴사 인자 수용체 (gitr) 항체 및 이의 이용 방법 |
| BR112019005633A8 (pt) | 2016-09-23 | 2023-04-11 | Hutchinson Fred Cancer Res | Tcrs específicos para antigênio ha-1 de histocompatibilidade (h) menor e usos dos mesmos |
| WO2018071913A2 (en) | 2016-10-14 | 2018-04-19 | Dana-Farber Cancer Institute, Inc. | Modular tetrameric bispecific antibody platform |
| WO2018089628A1 (en) | 2016-11-09 | 2018-05-17 | Agenus Inc. | Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof |
| CA3054885A1 (en) * | 2017-03-03 | 2018-09-07 | Rinat Neuroscience Corp. | Anti-gitr antibodies and methods of use thereof |
| SG11201908527SA (en) | 2017-03-15 | 2019-10-30 | Hutchinson Fred Cancer Res | High affinity mage-a1-specific tcrs and uses thereof |
| AR111651A1 (es) | 2017-04-28 | 2019-08-07 | Novartis Ag | Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación |
| KR20200006115A (ko) | 2017-05-16 | 2020-01-17 | 브리스톨-마이어스 스큅 컴퍼니 | 항-gitr 효능제 항체에 의한 암의 치료 |
| AU2018271991B2 (en) | 2017-05-24 | 2024-07-11 | Effector Therapeutics, Inc. | Compositions and methods for an improved antitumor immune response |
| WO2018229715A1 (en) | 2017-06-16 | 2018-12-20 | Novartis Ag | Compositions comprising anti-cd32b antibodies and methods of use thereof |
| CN110785187B (zh) | 2017-06-22 | 2024-04-05 | 诺华股份有限公司 | 针对cd73的抗体分子及其用途 |
| WO2018235056A1 (en) | 2017-06-22 | 2018-12-27 | Novartis Ag | Il-1beta binding antibodies for use in treating cancer |
| TW201904993A (zh) | 2017-06-22 | 2019-02-01 | 瑞士商諾華公司 | IL-1β 結合抗體之用途 |
| US20200172628A1 (en) | 2017-06-22 | 2020-06-04 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
| US20200223924A1 (en) | 2017-06-27 | 2020-07-16 | Novartis Ag | Dosage regimens for anti-tim-3 antibodies and uses thereof |
| CN110461874B (zh) | 2017-06-30 | 2022-04-12 | 江苏恒瑞医药股份有限公司 | 抗gitr抗体、其抗原结合片段及其医药用途 |
| IL319798A (en) | 2017-07-20 | 2025-05-01 | Novartis Ag | ANTI-LAG-3 Antibody Dosage Regimens and Their Uses |
| WO2019033057A1 (en) | 2017-08-11 | 2019-02-14 | Fred Hutchinson Cancer Research Center | SPECIFIC BRAF TCR AND USES THEREOF |
| US20200262894A1 (en) | 2017-09-06 | 2020-08-20 | Fred Hutchinson Cancer Research Center | Strep-tag specific binding proteins and uses thereof |
| AU2018327225A1 (en) | 2017-09-06 | 2020-02-27 | Fred Hutchinson Cancer Center | Strep-tag specific chimeric receptors and uses thereof |
| WO2019051135A1 (en) | 2017-09-06 | 2019-03-14 | Fred Hutchinson Cancer Research Center | METHODS FOR IMPROVING ADOPTIVE CELL THERAPY |
| US20210069241A1 (en) | 2017-10-20 | 2021-03-11 | Fred Hutchinson Cancer Research Center | Compositions and methods of immunotherapy targeting tigit and/or cd112r or comprising cd226 overexpression |
| US20210040205A1 (en) | 2017-10-25 | 2021-02-11 | Novartis Ag | Antibodies targeting cd32b and methods of use thereof |
| MX2020004756A (es) | 2017-11-16 | 2020-08-20 | Novartis Ag | Terapias de combinacion. |
| WO2019109047A1 (en) | 2017-12-01 | 2019-06-06 | Fred Hutchinson Cancer Research Center | Binding proteins specific for 5t4 and uses thereof |
| WO2019140278A1 (en) | 2018-01-11 | 2019-07-18 | Fred Hutchinson Cancer Research Center | Immunotherapy targeting core binding factor antigens |
| WO2019140229A1 (en) | 2018-01-12 | 2019-07-18 | Bristol-Myers Squibb Company | Antibodies against tim3 and uses thereof |
| BR112020016330A8 (pt) | 2018-02-12 | 2023-04-18 | Hutchinson Fred Cancer Res | Receptores de células t específicas a ciclina a1 e usos dos mesmos |
| CA3091138A1 (en) | 2018-02-26 | 2019-08-29 | Fred Hutchinson Cancer Research Center | Compositions and methods for cellular immunotherapy |
| EP3765070A4 (en) | 2018-03-14 | 2021-12-15 | Dana-Farber Cancer Institute, Inc. | SPECIFICALLY MODIFIED CELLS, T-LYMPHOCYTE IMMUNE MODULATION ANTIBODIES AND THEIR USE PROCEDURES |
| KR102874694B1 (ko) | 2018-03-21 | 2025-10-23 | 파이브 프라임 테라퓨틱스, 인크. | 산성 pH에서 VISTA에 결합하는 항체 |
| JP7611700B2 (ja) | 2018-03-27 | 2025-01-10 | ブリストル－マイヤーズ スクイブ カンパニー | 紫外線シグナルを使用した力価のリアルタイムモニタリング |
| US20210147547A1 (en) | 2018-04-13 | 2021-05-20 | Novartis Ag | Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof |
| AR126019A1 (es) | 2018-05-30 | 2023-09-06 | Novartis Ag | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación |
| CA3106380A1 (en) | 2018-05-31 | 2019-12-05 | Glyconex Inc. | Therapeutic antibodies |
| US20210214459A1 (en) | 2018-05-31 | 2021-07-15 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
| JP2021528393A (ja) | 2018-06-15 | 2021-10-21 | フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド | 後細胞シグナル伝達因子の調節による免疫活性の上昇 |
| EP3820904A2 (en) | 2018-07-09 | 2021-05-19 | Five Prime Therapeutics, Inc. | Antibodies binding to ilt4 |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| BR112020026947B1 (pt) | 2018-07-10 | 2022-11-22 | Novartis Ag | Derivados de 3-(5-hidróxi-1-oxoisoindolin-2-il)piperidina-2,6-diona, e composição farmacêutica |
| CN121203021A (zh) | 2018-07-11 | 2025-12-26 | 戊瑞治疗有限公司 | 在酸性pH下结合至VISTA的抗体 |
| WO2020018964A1 (en) | 2018-07-20 | 2020-01-23 | Fred Hutchinson Cancer Research Center | Compositions and methods for controlled expression of antigen-specific receptors |
| WO2020021465A1 (en) | 2018-07-25 | 2020-01-30 | Advanced Accelerator Applications (Italy) S.R.L. | Method of treatment of neuroendocrine tumors |
| KR20210049119A (ko) | 2018-08-22 | 2021-05-04 | 프레드 헛친슨 켄서 리서치 센터 | Kras 또는 her2 항원을 표적으로 하는 면역요법 |
| US20240165232A1 (en) | 2018-09-24 | 2024-05-23 | Fred Hutchinson Cancer Research Center | Chimeric receptor proteins and uses thereof |
| WO2020089811A1 (en) | 2018-10-31 | 2020-05-07 | Novartis Ag | Dc-sign antibody drug conjugates |
| KR20210102231A (ko) | 2018-11-09 | 2021-08-19 | 프레드 헛친슨 켄서 리서치 센터 | 메소텔린에 특이적인 t 세포 수용체 및 면역요법에서의 그의 용도 |
| CN111234018A (zh) * | 2018-11-29 | 2020-06-05 | 上海开拓者生物医药有限公司 | 全人抗gitr抗体及其制备方法 |
| JP7498714B2 (ja) | 2018-12-19 | 2024-06-12 | ヒューマブス・バイオメッド・ソシエテ・アノニム | Ｂ型肝炎ウイルスを中和する抗体およびその使用 |
| BR112021011874A2 (pt) | 2018-12-20 | 2021-09-08 | Novartis Ag | Regime de dosagem e combinação farmacêutica compreendendo derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona |
| WO2020128613A1 (en) | 2018-12-21 | 2020-06-25 | Novartis Ag | Use of il-1beta binding antibodies |
| CA3119584A1 (en) | 2018-12-21 | 2020-06-25 | Novartis Ag | Use of il-1 beta antibodies in the treatment or prevention of myelodysplastic syndrome |
| CA3119582A1 (en) | 2018-12-21 | 2020-06-25 | Novartis Ag | Use of il-1.beta. binding antibodies |
| WO2020128637A1 (en) | 2018-12-21 | 2020-06-25 | Novartis Ag | Use of il-1 binding antibodies in the treatment of a msi-h cancer |
| WO2020165833A1 (en) | 2019-02-15 | 2020-08-20 | Novartis Ag | 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| AU2020222346B2 (en) | 2019-02-15 | 2021-12-09 | Novartis Ag | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| KR20210130189A (ko) | 2019-02-20 | 2021-10-29 | 프레드 헛친슨 켄서 리서치 센터 | Ras 신항원에 특이적인 결합 단백질 및 이의 용도 |
| WO2020172658A1 (en) | 2019-02-24 | 2020-08-27 | Bristol-Myers Squibb Company | Methods of isolating a protein |
| CN113784978B (zh) | 2019-03-11 | 2025-07-25 | 弗雷德哈钦森癌症中心 | 高亲合力wt1 t细胞受体及其用途 |
| WO2020227159A2 (en) | 2019-05-03 | 2020-11-12 | Flagship Pioneering Innovations V, Inc. | Methods of modulating immune activity |
| EP3973274A1 (en) | 2019-05-23 | 2022-03-30 | Bristol-Myers Squibb Company | Methods of monitoring cell culture media |
| JP7737978B2 (ja) | 2019-08-20 | 2025-09-11 | フレッド ハッチンソン キャンサー センター | Ｗｔ－１に特異的なｔ細胞免疫療法 |
| AU2020336980B2 (en) | 2019-08-29 | 2025-07-10 | Vir Biotechnology, Inc. | Antibody compositions and methods for treating hepatitis B virus infection |
| JP2022548881A (ja) | 2019-09-18 | 2022-11-22 | ノバルティス アーゲー | Ｅｎｔｐｄ２抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法 |
| EP4031575A1 (en) | 2019-09-19 | 2022-07-27 | Bristol-Myers Squibb Company | Antibodies binding to vista at acidic ph |
| CN114786679A (zh) | 2019-10-21 | 2022-07-22 | 诺华股份有限公司 | 具有维奈托克和tim-3抑制剂的组合疗法 |
| JP2022553306A (ja) | 2019-10-21 | 2022-12-22 | ノバルティス アーゲー | Ｔｉｍ－３阻害剤およびその使用 |
| US20230114107A1 (en) | 2019-12-17 | 2023-04-13 | Flagship Pioneering Innovations V, Inc. | Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly |
| CN115175937A (zh) | 2019-12-20 | 2022-10-11 | 诺华股份有限公司 | 用于治疗骨髓纤维化和骨髓增生异常综合征的抗TIM-3抗体MBG453和抗TGF-β抗体NIS793与或不与地西他滨或抗PD-1抗体斯巴达珠单抗的组合 |
| CN114901695A (zh) * | 2020-01-02 | 2022-08-12 | 南京金斯瑞生物科技有限公司 | 抗gitr抗体及其用途 |
| KR20220128389A (ko) | 2020-01-17 | 2022-09-20 | 노파르티스 아게 | 골수이형성 증후군 또는 만성 골수단핵구성 백혈병을 치료하는데 사용하기 위한 tim-3 억제제 및 저메틸화제를 포함하는 조합물 |
| IL296043A (en) | 2020-03-06 | 2022-10-01 | Regeneron Pharma | Anti-gitro antibodies and their uses |
| JPWO2021225159A1 (cg-RX-API-DMAC7.html) * | 2020-05-08 | 2021-11-11 | ||
| KR20230024967A (ko) | 2020-06-11 | 2023-02-21 | 노파르티스 아게 | Zbtb32 억제제 및 이의 용도 |
| CA3182346A1 (en) | 2020-06-23 | 2021-12-30 | Novartis Ag | Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
| KR20230042023A (ko) | 2020-06-24 | 2023-03-27 | 비르 바이오테크놀로지, 인코포레이티드 | 조작된 b형 간염 바이러스 중화 항체 및 이의 용도 |
| CN111732658B (zh) * | 2020-06-28 | 2022-04-26 | 英诺湖医药(杭州)有限公司 | 一组gitr单克隆抗体及其医药用途 |
| CA3184366A1 (en) | 2020-06-29 | 2022-01-06 | Darby Rye Schmidt | Viruses engineered to promote thanotransmission and their use in treating cancer |
| US20230271940A1 (en) | 2020-08-03 | 2023-08-31 | Novartis Ag | Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| EP4204020A1 (en) | 2020-08-31 | 2023-07-05 | Advanced Accelerator Applications International S.A. | Method of treating psma-expressing cancers |
| US20230321285A1 (en) | 2020-08-31 | 2023-10-12 | Advanced Accelerator Applications International Sa | Method of treating psma-expressing cancers |
| US20250018036A1 (en) | 2020-09-24 | 2025-01-16 | Fred Hutchinson Cancer Center | Immunotherapy targeting sox2 antigens |
| WO2022066973A1 (en) | 2020-09-24 | 2022-03-31 | Fred Hutchinson Cancer Research Center | Immunotherapy targeting pbk or oip5 antigens |
| US20230374064A1 (en) | 2020-10-05 | 2023-11-23 | Bristol-Myers Squibb Company | Methods for concentrating proteins |
| TW202222841A (zh) | 2020-10-06 | 2022-06-16 | 福瑞德哈金森腫瘤研究中心 | 用於治療表現mage-a1之疾病的組成物及方法 |
| US20240018248A1 (en) | 2020-12-02 | 2024-01-18 | Vib Vzw | An ltbr agonist in combination therapy against cancer |
| WO2022132836A2 (en) | 2020-12-14 | 2022-06-23 | Fred Hutchinson Cancer Research Center | Compositions and methods for cellular immunotherapy |
| WO2022164805A1 (en) | 2021-01-26 | 2022-08-04 | Vir Biotechnology, Inc. | Compositions and methods for treating hepatitis b virus infection |
| CA3214085A1 (en) | 2021-03-31 | 2022-10-06 | Darby Rye Schmidt | Thanotransmission polypeptides and their use in treating cancer |
| TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途 |
| AR125874A1 (es) | 2021-05-18 | 2023-08-23 | Novartis Ag | Terapias de combinación |
| CA3224374A1 (en) | 2021-06-29 | 2023-01-05 | Flagship Pioneering Innovations V, Inc. | Immune cells engineered to promote thanotransmission and uses thereof |
| WO2023288281A2 (en) | 2021-07-15 | 2023-01-19 | Fred Hutchinson Cancer Center | Chimeric polypeptides |
| KR20240156411A (ko) | 2022-03-09 | 2024-10-29 | 브리스톨-마이어스 스큅 컴퍼니 | 치료 단백질의 일시적 발현 |
| EP4493195A1 (en) | 2022-03-15 | 2025-01-22 | Compugen Ltd. | Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer |
| WO2023215725A1 (en) | 2022-05-02 | 2023-11-09 | Fred Hutchinson Cancer Center | Compositions and methods for cellular immunotherapy |
| WO2023230439A1 (en) | 2022-05-23 | 2023-11-30 | Vir Biotechnology, Inc. | Fc-engineered hepatitis b virus neutralizing antibodies and uses thereof |
| WO2024077191A1 (en) | 2022-10-05 | 2024-04-11 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer |
| US20240269251A1 (en) | 2023-01-09 | 2024-08-15 | Flagship Pioneering Innovations V, Inc. | Genetic switches and their use in treating cancer |
| TW202515608A (zh) | 2023-06-26 | 2025-04-16 | 以色列商坎布根有限公司 | Ｉｌ—１８ｂｐ拮抗抗體及其於癌症治療之單一療法及組合療法的用途 |
| WO2025081123A1 (en) | 2023-10-12 | 2025-04-17 | Fred Hutchinson Cancer Center | Methods and compositions for improving t cell immunotherapy |
| WO2025101820A1 (en) | 2023-11-08 | 2025-05-15 | Fred Hutchinson Cancer Center | Compositions and methods for cellular immunotherapy |
| WO2025245169A1 (en) | 2024-05-21 | 2025-11-27 | Fred Hutchinson Cancer Center | Immunotherapy cells equipped with a collagen-targeting payload |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| EP0279862B1 (en) | 1986-08-28 | 1993-11-03 | Teijin Limited | Cytocidal antibody complex and process for its preparation |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| AU641673B2 (en) | 1989-06-29 | 1993-09-30 | Medarex, Inc. | Bispecific reagents for aids therapy |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| WO1992003918A1 (en) | 1990-08-29 | 1992-03-19 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| CA2102511A1 (en) | 1991-05-14 | 1992-11-15 | Paul J. Higgins | Heteroconjugate antibodies for treatment of hiv infection |
| WO1993004701A1 (en) | 1991-09-05 | 1993-03-18 | University Of Connecticut | Targeted delivery of poly- or oligonucleotides to cells |
| NZ255101A (en) | 1992-07-24 | 1997-08-22 | Cell Genesys Inc | A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor |
| DE69329503T2 (de) | 1992-11-13 | 2001-05-03 | Idec Pharma Corp | Therapeutische Verwendung von chimerischen und markierten Antikörpern, die gegen ein Differenzierung-Antigen gerichtet sind, dessen Expression auf menschliche B Lymphozyt beschränkt ist, für die Behandlung von B-Zell-Lymphoma |
| CA2183667A1 (en) | 1994-02-22 | 1995-08-24 | Wayne A. Marasco | Nucleic acid delivery system, method of synthesis and uses thereof |
| ATE390933T1 (de) | 1995-04-27 | 2008-04-15 | Amgen Fremont Inc | Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8 |
| WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| US20020029391A1 (en) | 1998-04-15 | 2002-03-07 | Claude Geoffrey Davis | Epitope-driven human antibody production and gene expression profiling |
| CN1871259A (zh) | 2003-08-22 | 2006-11-29 | 比奥根艾迪克Ma公司 | 具有改变的效应物功能的经改进的抗体和制备它的方法 |
| WO2005047327A2 (en) | 2003-11-12 | 2005-05-26 | Biogen Idec Ma Inc. | NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO |
| DK1866339T3 (da) | 2005-03-25 | 2013-09-02 | Gitr Inc | GTR-bindende molekyler og anvendelser heraf |
| CN101218257A (zh) * | 2005-03-25 | 2008-07-09 | 托勒克斯股份有限公司 | Gitr结合分子及其用途 |
| EP1981969A4 (en) * | 2006-01-19 | 2009-06-03 | Genzyme Corp | ANTI-GITRANT ANTIBODIES FOR THE TREATMENT OF CANCER |
| JP2008278814A (ja) * | 2007-05-11 | 2008-11-20 | Igaku Seibutsugaku Kenkyusho:Kk | アゴニスティック抗ヒトｇｉｔｒ抗体による免疫制御の解除とその応用 |
| IN2012DN01920A (cg-RX-API-DMAC7.html) * | 2009-09-03 | 2015-07-24 | Schering Corp | |
| AU2010328347B2 (en) * | 2009-12-07 | 2015-12-17 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for enhancing anti-tumor antibody therapy |
| WO2013039954A1 (en) | 2011-09-14 | 2013-03-21 | Sanofi | Anti-gitr antibodies |
-
2015
- 2015-10-05 WO PCT/US2015/054010 patent/WO2016054638A1/en not_active Ceased
- 2015-10-05 AU AU2015327781A patent/AU2015327781A1/en not_active Abandoned
- 2015-10-05 US US15/516,272 patent/US10463732B2/en active Active
- 2015-10-05 JP JP2017517707A patent/JP2017531427A/ja active Pending
- 2015-10-05 RU RU2017115315A patent/RU2017115315A/ru not_active Application Discontinuation
- 2015-10-05 CA CA2962976A patent/CA2962976A1/en not_active Abandoned
- 2015-10-05 KR KR1020177010603A patent/KR20170062485A/ko not_active Withdrawn
- 2015-10-05 CN CN201580065829.2A patent/CN107250159A/zh active Pending
- 2015-10-05 MX MX2017004311A patent/MX2017004311A/es unknown
- 2015-10-05 BR BR112017006825A patent/BR112017006825A2/pt not_active Application Discontinuation
- 2015-10-05 EP EP15781278.5A patent/EP3201232A1/en not_active Withdrawn
-
2017
- 2017-03-26 IL IL251389A patent/IL251389A0/en unknown
-
2019
- 2019-11-04 US US16/672,763 patent/US20200261578A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2017531427A (ja) | 2017-10-26 |
| KR20170062485A (ko) | 2017-06-07 |
| WO2016054638A1 (en) | 2016-04-07 |
| US20200261578A1 (en) | 2020-08-20 |
| AU2015327781A1 (en) | 2017-04-20 |
| US20170304444A1 (en) | 2017-10-26 |
| EP3201232A1 (en) | 2017-08-09 |
| IL251389A0 (en) | 2017-05-29 |
| RU2017115315A (ru) | 2018-11-08 |
| RU2017115315A3 (cg-RX-API-DMAC7.html) | 2019-10-10 |
| CN107250159A (zh) | 2017-10-13 |
| CA2962976A1 (en) | 2016-04-07 |
| BR112017006825A2 (pt) | 2017-12-12 |
| US10463732B2 (en) | 2019-11-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2017004311A (es) | Anticuerpos del receptor del factor de necrosis tumoral inducido por glucocorticoide (gitr) y metodos de uso de los mismos. | |
| ZA201708265B (en) | Tigit-binding agents and uses thereof | |
| PH12018502502A1 (en) | Anti-gitr antibodies and uses thereof | |
| EP4417263A3 (en) | Cd3 binding antibodies | |
| MX2021003704A (es) | Anticuerpos heterodimericos que se unen a cd3 y a antigenos tumorales. | |
| GEP20227440B (en) | Anti-ilt4 antibodies and antigen-binding fragments | |
| PH12016502267A1 (en) | Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof | |
| SA517381703B1 (ar) | C10orf54 - أجسام مضادة لـ واستخداماتها | |
| PH12017502019B1 (en) | Heterodimeric antibodies that bind cd3 and tumor antigens | |
| GEP20227343B (en) | Anti-lag3 antibodies and antigen-binding fragments | |
| PH12016501644B1 (en) | Binding proteins and methods of use thereof | |
| JOP20200312A1 (ar) | الأجسام المضادة للعامل xi وطرق الاستخدام | |
| MX2019015738A (es) | Regimen de dosificacion para anticuerpos anti-tim-3 y usos de los mismos. | |
| NZ764826A (en) | Anti-gitr antibodies and methods of use thereof | |
| MX2015004105A (es) | Anticuerpos monoclonales humanos anti-pd-l1 y metodos de uso. | |
| NZ730186A (en) | Humanized anti-hepcidin antibodies and uses thereof | |
| MX2024003627A (es) | Anticuerpos contra el receptor del factor de necrosis tumoral inducido por glucocorticoides (gitr) y sus metodos de uso. | |
| MX2016014726A (es) | Proteinas de union al antigeno her1 que se unen a la beta-horquilla de her1. | |
| HK40093127A (zh) | 结合cd3和肿瘤抗原的异二聚体抗体 | |
| HK40065611A (zh) | 结合cd3和肿瘤抗原的异二聚体抗体 | |
| EA201792460A1 (ru) | Связывающие tigit агенты и варианты их применения | |
| EA202092450A2 (ru) | Комбинирование anti-lag-3-антител и анти-pd-1-антител для лечения опухолей |